DexCom (DXCM)
(Delayed Data from NSDQ)
$116.06 USD
+3.05 (2.70%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $116.06 0.00 (0.00%) 7:12 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Brokerage Reports
DexCom, Inc. [DXCM]
Reports for Purchase
Showing records 381 - 400 ( 413 total )
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Frustrating CGM adoption rate continues; Q2 beat consensus on grant revenue
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
Reports Decent Q2 Financials. Core Business Continues To Perform Well and Gen4 on Track for Mid-2012 Launch.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
FDA releases draft guidelines for artificial pancreas system precursor
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Q1 Financials In-Line With Strong Demand Exiting Quarter.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Q4 Financials: Core Business Remains Solid With Potential for Upside to Guidance in 2011. Raising Fair Value to $17.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Q4:10 Preannouncement and 2011 Guidance Both Positive In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
Company: DexCom, Inc.
Industry: Medical - Products
INCREASED FDA SCRUTINY LEADING TO LONGER APPROVAL TIMES
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J